Sopalol 2.5/Sopalol 5

Sopalol 2.5/Sopalol 5 Drug Interactions



Intas Pharmaceuticals


Berlin Pharm
Full Prescribing Info
Drug Interactions
Metabolism/Transport effects: Substrate of CYP2D6 (minor), CYP3A4 (major). Assignment of major/minor substrate status based on clinically relevant drug interaction potential (Sopalol 2.5 only).
Avoid concomitant use of bisoprolol with any of the following drugs: Conivaptan, floctafenine, methacholine.
Increased effect/toxicity: Bisoprolol may increase the levels/effects of alpha-/beta-agonists (direct-acting), alpha 1-blockers, alpha 2-agonists, amifostine, antihypertensives, antipsychotic agents (phenothiazines), bupivacaine, cardiac glycosides, cholinergic agonists, ergot derivatives, fingolimod, hypotensive agents, insulin, lidocaine (systemic), lidocaine (topical), mepivacaine, methacholine, midodrine, rituximab, sulfonylureas.
Sopalol 5: Oral anti-diabetic medicines, mefloquine.
The levels/effects of bisoprolol may be increased by acetylcholinesterase inhibitors, alpha 2-agonists, aminoquinolines (antimalarial), amiodarone, anilidopiperidine, opioids, antipsychotic agents (phenothiazines), calcium channel blockers (dihydropyridine), calcium channel blockers (nondihydropyridine), conivaptan, CYP3A4 inhibitors (moderate), CYP3A4 inhibitors (strong), dasatinib, diazoxide, dipyridamole, disopyramide, dronedarone, floctafenine, herbs (hypotensive properties), ivacaftor, MAO inhibitors, mifepristone, pentoxyfylline, phosphodiesterase 5 inhibitors, propafenone, prostacyclin analogues, quinidine, reserpine.
Sopalol 5: Flecainide, phenytoin, topical beta-blockers (eye drops for glaucoma treatment), anaesthetic agents, antihypertensive agents and other medicines with blood pressure lowering potential (tricyclic anti-depressants, barbiturates, phenothiazines).
Decreased effect: Bisoprolol may decrease the levels/effects of beta 2-agonists (e.g. salbutamol, terbutaline, salmeterol, procaterol, etc.), theophylline derivatives.
The levels/effects of bisoprolol may be decreased by barbiturates, CYP3A4 inducers (strong), deferasirox, herbs (enzyme CYP3A4 inducers e.g. St. Johns Wort), herbs (hypertensive properties), methylphenidate, nonsteroidal anti-inflammatory agents, peginterferon alfa-2b, rifamycin derivatives, tocilizumab, yohimbine.
Ethanol/Nutrition/Herb interaction: Herb/Nutraceutical: Avoid dong quai if using for hypertension (has estrogenic activity). Avoid ephedra, yohimbe, ginseng (may worsen hypertension). Avoid garlic (may have increased antihypertensive effect).
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in